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Abstract. Cyclosporine A is a noncytotoxic, natural, 
11 amino acid cyclic peptide used clinically as an 
immunosuppressant to prevent organ rejection after 
transplantation.  Cyclosporine A is an in vitro calmod- 
ulin antagonist. At the low concentrations required to 
inhibit calmodulin-dependent phosphodiesterase in vi- 
tro, cyclosporine A causes a dramatic alteration in the 
nuclear morphology of 23% of human peripheral 
blood mononuclear leukocytes in vitro without loss of 
viability. The shape of the nucleus changes from 
ovoid to a distinctive, radially splayed lobulated struc- 
ture. The changes occur in a dose-dependent manner 
in 60 min at 37°C. Specific monoclonal antibodies to 
human leukocytes identify the cells susceptible to nu- 
clear lobulation by cyclosporine A as OKT4 antigen- 
positive T cell lymphocytes and monocytes. The lobu- 
lated nuclei are 2N as determined by flow cytometric 
measurement of ethidium bromide fluorescence of 
DNA. The cyclosporine A-induced lobulation of T 
cell nuclei requires both physiologic temperature and 
metabolic energy. Although structurally different than 
cyclosporine A, the calmodulin antagonists R24571 
and W-7 [N-(6-aminohexyl)-5-chloro-l-naphthalene- 
sulfonamide] also produce T cell nuclear lobulations 
that are indistinguishable from the nuclear lobulations 
caused by cyclosporine A. These data indicate that 
nonmitotic structural elements that govern normal 
nuclear morphology in a subset of mononuclear leu- 
kocytes appear to require a calmodulin-mediated 
process. Cyclosporine A may be a useful noncytotoxic 
inhibitor of calmodulin-dependent systems that influ- 
ence nuclear structure and function. 
C 
YCLOSPORINE  A (CsA)  ~  is a natural  cyclic endecapep- 
tide derived from the Tolypocladium inflatum fungus 
with profound clinical and experimental immunosup- 
pressive properties. CsA is employed widely in the treatment 
of graft-versus host disease after bone marrow transplantation 
and for graft  rejection  in  solid organ  transplantation.  This 
drug  is now under  investigation  as a  potential  therapeutic 
agent  in  autoimmune disease, malaria,  and schistosomiasis 
(2, 3). The mechanism  by which CsA exerts its immunosup- 
pressive action remains elusive. Recently CsA has been dem- 
onstrated  to be a calmodulin-specific antagonist  in the brain 
Abbreviations used in this paper." CsA, cyclosporine A; dansCsA, a dansylated 
derivative of native CsA; NM1, nuclear morphology index; W-7 N-(6-amino- 
hexyl)-5-chloro-l-naphthalene-sulfonamide. 
phosphodiesterase  in vitro system (6). Furthermore,  the cal- 
modulin  antagonists  W-7  [N-(6-aminohexyl)-5-chloro-1- 
naphthalene-sulfonamide]  and  R24571  prevent  binding  of 
CsA to T lymphocyte clones. CsA has a specific cytosolic 15K 
binding protein, cyclophilin; this highly basic receptor protein 
for CsA shows no NH2 terminal  amino acid  sequence  ho- 
mology  to any published  protein  sequence  (10). Recently, 
cyclosporine A was found to selectively inhibit  the normal 
accumulation of T cell growth factor or interleukin-2 mRNA 
in  T lymphocyte cell lines stimulated  by phorbol  myristate 
acetate (9). These data suggest that the mechanism  of action 
of CsA may be within the nucleus  of the T cell, preventing 
transcription  or causing posttranscriptional  destabilization of 
message. 
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with equivalent potency as an in vitro calmodulin antagonist 
are  herein  reported  to  alter  the  nuclear  morphology of a 
subpopulation of human peripheral blood mononuclear leu- 
kocytes. The nuclear morphologic changes occurred at 37°C 
within 1 h of drug exposure but without apparent loss of cell 
viability as assessed by trypan blue dye exclusion. 
The cells with nuclei susceptible to cyclosporine A-induced 
nuclear lobulation were identified as OKT4 ÷ (helper) T cells 
and  monocytes.  The  following studies  were  undertaken to 
begin characterization of the effect of CsA on nuclear struc- 
ture. 
Materials and Methods 
Human  peripheral blood  mononuclear leukocytes were  obtained by  Ficoll- 
Hypaque isolation and washed three times in  Ca++-free  phosphate-buffered 
saline (PBS).  CsA (OL-27-400) and dansCsA (205-797) were generous gifts of 
Sandoz Ltd. (Basel, Switzerland). Drug concentration was  1 ~M in Ca+÷-free 
PBS,  pH  7.4,  in all experiments. Stained with the fluorescent dansCsA, cells 
were sorted into dim and bright staining populations with the FACS-Ii analyzer 
(Becton  Dickinson FACS,  Oxnard,  CA) using ultraviolet  excitation (5,  11). 
Unfractionated peripheral blood mononuclear leukocytes were used in both 
the time-course and inhibitor experiments. To inhibit energy-dependent  proc- 
esses, cells were pretreated for 2 h at 37"C with dinitrophenol at 0.5 mg/ml of 
2-deoxyglucose at  1 mg/ml. The calmodulin inhibitor R-24571  was obtained 
from  Boehringer Mannheim Biochemicals (Mannheim,  Federal  Republic of 
Germany), and W-7 was acquired from Sigma Chemical Co. (St. Louis, MO). 
Viability before  and after  CsA treatment  was assessed  by trypan  blue dye 
exclusion in early experiments; this consistently yielded >95% dye impermeable 
cells. Cells were prepared  for  nuclear morphometrics by cytocentrifugation. 
Wright-Giemsa staining immediately followed centrifugation at the conclusion 
of each incubation. To determine whether CsA-induced nuclear lobulation was 
influenced by DNA replication, leukocyte nuclear DNA content was assessed 
by ethidium bromide fluorescence using a FACS-II cytofluorimeter (17). 
To quantitate nuclear shape change, morphometrics were performed with 
computer-assisted image analysis, extensively  described elsewhere (8).  Nuclear 
image analysis was performed under oil immersion using a Zeiss planapoch- 
romat 100x objective and a  12.5x ocular. With an affixed Zeiss camera lucida 
(model 47462) and a  Hewlett-Packard 9874A digitizer pad (Hewlett-Packard 
Co.),  nuclear perimeter was traced using a  small green light-emitting diode 
(model 276-037. Radio Shack Div., Tandy Corp., Fort Worth, TX) attached to 
the digitizer puck.  A  Hewlett-Packard 9825  digital computer was calibrated 
using  a  Zeiss  stage  micrometer graduated  in  0.l-mm  units.  From  points 
generated by nuclear tracing, the computer calculated nuclear perimeter, nu- 
clear cross-sectional area,  and  a  nuclear morphology index (NM1)  for each 
nucleus.  The  NMI  is  calculated from  two  computed  radii:  Rc,  the  radius 
computed for a  circle with a  circumference (C) equal to  the traced nuclear 
perimeter; and rA, the radius computed for a circle with an area (A) equal to 
the traced nuclear cross-sectional area. Thus, where C is the circumference and 
A is area. (Rc/rA)  =  C/2~r/(A/r) ~/2 of the digitizer traced nuclei. A perfectly 
circular nucleus would have a Rc/rA of 1.000. 
In this system with 10 successive tracings, a geometrically accurate circle of 
known area of 30 ~m  2 and an Rc/rA of 1.000 can be computed to have an area 
of 30.5 um  2 -+ 0.1  SD and an Rc/rA  of 1.006  -+ 0.001  SD (13).  To express 
deviation from nuclear circularity, NMI units are expressed as (Rc/rA -  1.000) 
x  103. A  perfectly circular nucleus would have an NMI value of zero. As the 
NMI  value  increased  it denoted  increasing deviation from  circularity, i.e., 
Iobulation.  100 nuclei were digitized from each cytocentrifuged slide of periph- 
eral blood leukocytes, and the mean and SEM of NMI were calculated. 
The immunocytochemistry  studies used methods similar to those described 
by Martin et al. (13). Cell suspensions were counted and checked for viability. 
The cell count was adjusted to ~5 x  104/ml and polyethylene glycol was added 
to a  final concentration of 10%.  The cells were attached to glass slides  using 
the Shandon cytospin (Shandon Southern Instruments Inc., Sewickley, PA) at 
700 rpm  for  5  min.  The slides  were air dried and  fixed with acetone.  The 
monoclonal antibodies used included HLel, Leul, and Leul2 (Becton-Dick- 
inson  &  Co.,  Sunnyvale, CA),  OKTI1,  OKT4,  OKT8  and  OKMI  (Ortho 
Diagnostics, Raritan,  N J),  BI  (Coulter Electronics Inc.,  Hiahleah, FL),  and 
anti-Tac (kindly provided by Dr. T. Waldmann, National Institutes of Health). 
Biotinylated horse anti-mouse IgG (Vector Laboratories, Burlingame, CA) was 
used as the second antibody. In addition, biotin-conjugated goat anti-mu heavy 
chain (Tago Inc., Budingame, CA) was used for surface IgM. The dilutions of 
the primary antibodies varied from 1:20 to  1:100, depending on the antibody 
lot. 
The avidin-biotin  complex staining methods have been described previously 
(1,  12). The  slides  were  again  fixed  with  acetone  and  washed with  PBS 
containing 0.2% bovine serum albumin. After the slides were washed they were 
incubated for 30 min with the monoclonal  antibody  and washed again. Negative 
controls were incubated with unrelated antibody.  Endogenous peroxidase was 
inactivated  with  methanol and  hydrogen  peroxide.  The  section  antibody, 
biotinylated horse anti-mouse lgG (1:50), was layered for 30 min and the slides 
were washed. The sections were exposed to the avidin-biotin  complex (30 min), 
developed with diaminobenzidine  (25 min or as indicated by HLe 1) and copper 
sulfate (5 rain), and counterstained  with a fast Giemsa stain. 
Results 
CsA and dansCsA caused profound changes in mononuclear 
leukocyte  nuclear  morphology without  loss  of viability  as 
assessed by  trypan blue  dye  exclusion  (Fig.  1).  The  ovoid 
nuclei became distinctively  lobulated by CsA.  The affected 
nuclei  appeared by  light  microscopy as splayed  lobules at- 
tached to a  1-2-#m axle of central chromatin. As many as 20 
separate lobes could be observed in one nucleus in some of 
the drug-treated cells. 
The  dramatic  lobulation  of  nuclear  morphology  by 
dansCsA appeared in a  subpopulation of mononuclear leu- 
kocytes in peripheral blood. Nuclear lobulation provoked by 
dansCsA was evident in 21  _  9%  (mean _+ SEM) of cells as 
opposed to the untreated control group, which had 3 _+  1% 
(mean _+ SEM) of cells meeting the criterion of three or more 
nuclear lobulations. 
The striking nuclear lobulation of mononuclear leukocytes 
was induced by dansCsA in a dose-dependent manner (Fig. 
2). Structurally dissimilar calmodulin inhibitors R24571  and 
W-7  also  caused  human  leukocyte  nuclear  lobulations  in 
identical incubation conditions. The concentrations of drug 
required for half-maximal induction of nuclear lobulation for 
dansCsA,  R24571,  and  W-7  all  fall  in  the  1-2  x  10 -7  M 
range,  although  dansCsA  induced  twice  as  many  cells  to 
undergo lobulation. This drug concentration range for W-7 
and dansCsA has been shown to be sufficient for competitive 
inhibition  of calmodulin-dependent  phosphodiesterase  (6). 
The concentration ofdansCsA to give a half-maximal number 
of cells with lobulated nuclei is remarkably comparable to the 
Ko for dansCsA binding to calmodulin in vitro (2 x  10 -7 M) 
and the KD of CsA binding T  lymphocytes (2-3  x  10  -7  M) 
(4, 6,  15). 
A  twofold  enrichment  of  mononuclear  leukocytes  that 
undergo nuclear lobulation was achieved by dansCsA staining 
and sorting through a FACS-II system. The use of the fluo- 
rescent CsA probe allows for the isolation of T cells that have 
a  differential  binding  capacity  for  CsA;  of these,  cells  are 
either intensely or weakly fluorescent (5). Although compris- 
ing only  18%  of the human peripheral blood mononuclear 
leukocytes,  the  bright-staining  cells  contained  95%  of the 
lobulated nuclei observed in both bright and dim populations. 
The bright population has been shown to contain B lympho- 
cytes, OKT4+  and OKT8+  T  lymphocytes, and monocytes 
(5).  Drug  uptake  assessed  by  high  dansCsA  fluorescence, 
however, is not sufficient alone to induce lobulation, as 43% 
of the bright population nuclei were not lobulated. 
The kinetics of CsA-induced lobulation were characterized 
by time-course experiments using computer-assisted morpho- 
metrics  (see  Materials  and  Methods)  (Fig.  3).  At  1.0  #M 
concentration, dansCsA caused a  15-fold increase in mono- 
nuclear leukocyte mean NMI. The maximum effect of lobu- 
The Journal of Cell Biology, Volume 102,  1986  146 Figure  1.  Photomicrographs comparing untreated and treated human mononuclear leukocyte nuclei. Human peripheral blood mononuclear 
leukocytes were incubated in PBS at 37* for 1 h in the absence (A) and presence (B) of I #M CsA. Cells were >95% viable by trypan blue dye 
exclusion at the conclusion of the experiment. Leukocytes were stained by Wright Giemsa after cytocentrifugation. Bar, 8 um. 
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Figure 2.  Dose  response  of dansCsA,  R24571,  and  W-7  on  the 
induction  of nuclear  lobulation  in  peripheral  blood  mononuclear 
cells. Cells were incubated for 1 h at 37"C in various concentrations 
of drugs before cytocentrifugation and staining. The concentrations 
of each  drug  yielding half-maximal  percent  of cells with  nuclear 
lobulations  were  calculated  by  regression  analysis;  the  values  for 
dansCsA,  R24571,  and W-7 were 0.12, 0.15, and 0.18 ,M,  respec- 
tively. 
lation was observed at 60 min. Over 80% of the alteration in 
NMI index of mononuclear leukocytes treated with dansCsA 
occurred within  the  first  30  min  of treatment.  Despite  the 
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Figure 3.  Time course of nuclear lobulation caused by CsA. Unfrac- 
tionated human mononuclear leukocytes were incubated with 1 ,M 
dansCsA and assessed  for changes in nuclear morphology at various 
time points.  NM1 is expressed in units of (Rc/rA  -  1.000)  x  1,000 
(see  Materials  and  Methods).  The  perimeters  of  100  nuclei  were 
digitized through computer-assisted morphometrics, and mean NMI 
and SEM were computed at each time point. Viability by trypan blue 
dye exclusion was >95%. 
prominent changes in  nuclear morphology, cell  viability  as 
assessed by trypan blue exclusion was greater than 95 %. CsA- 
provoked nuclear lobulation appeared to be transient, as NMI 
returned to the untreated  value by 4 h.  Incubation in PBS 
alone, however, did not cause any significant  changes. 
To determine whether or not susceptibility  to nuclear lob- 
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Figure 4.  FACS II histogram plots of 
2N ethidium bromide DNA fluores- 
cence distribution in dansCsA-treated 
human mononuclear leukocytes. (A) 
Human  peripheral blood leukocytes 
were stained with 1.0  #M  dansCsA 
and assessed directly  for ethidium bro- 
mide DNA fluorescence  (see Materials 
and  Methods).  Leukocytes were 
FACS-II  sorted into (B)  a  dim 
dansCsA fluorescence population and 
(C)  a  bright dansCsA fluorescence 
population.  The  dim  and  bright 
dansCsA-stained leukocytes  were then 
assayed for ethidium bromide DNA 
fluorescence. The  total numbers of 
cells counted for A-C  were 14,871, 
14,901, and 14,895, respectively. 
of treatment, when the nuclear change was maximal (Fig. 5). 
The extent of lobulation, induced by CsA as determined by 
NMI, was almost identical  to that  induced by dansCsA at 
37°C. Microscopically,  the lobulated mononuclear leukocyte 
nuclei  induced by CsA and dansCsA were  indistinguishable 
from each other. The kinetics  of nuclear morphologic index 
changes in the presence of CsA appear identical  at 0, 30, and 
60  min  to  those  of dansCsA  at  3"?*C in  Fig.  3  (data  not 
presented),  indicating that the dansyl groups on dansCsA do 
not influence the nuclear lobulation in themselves. 
Nuclear lobulation by CsA showed temperature  depend- 
ence. Incubation of mononuclear leukocytes at 4"C in  1 ~M 
CsA prevented any change in nuclear morphology. In addition 
to being temperature dependent, CsA-induced nuclear lobu- 
lation  apparently  also  required  metabolic energy.  Pretreat- 
ment with the mitochondrial uncoupler dinitrophenol and 2- 
deoxyglucose for  2  h  in  PBS  caused  a  60%  inhibition  in 
nuclear lobulation  after a  1-h  incubation  in  CsA at  37"C. 
Complete abolition of CsA-induced nuclear lobulation in the 
sensitive leukocyte subpopulation occurred in the presence of 
the  metabolic  inhibitor  sodium  azide  at  0.1%  (data  not 
shown). 
The  calmodulin  inhibitor  R24571  at  1 #M  caused  an 
increase  in mean NMI slightly greater than that caused by 
CsA or dansCsA in  1 h  at  37"C. By light  microscopy, the 
nuclei  lobulated  by R24571  mononuclear leukocytes were 
similar to those treated with CsA. Viability  of leukocytes at 1 
h at 37"C was 82% as assessed by trypan blue dye exclusion 
in the presence of R24571  as opposed to >95% viable in CsA 
at the same concentration. 
To assess the phenotypes of cells demonstrating lobulated 
nuclei, peripheral  blood lymphocytes incubated with CsA (60 
min, 37°C) were stained (immunoperoxidase) with a panel of 
monoclonal antibodies.  The results  shown in Table I dem- 
onstrate that most (70%) cells demonstrating lobulated nuclei 
were T lymphocytes that expressed  the OKT4  ÷ antigen.  The 
remaining cells  that  showed CsA-induced lobulated  nuclei 
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R24~7~ 
37*  3~ 
ulation by CsA might be influenced by chromosomal repli- 
cation,  ethidium  bromide  fluorescence  of  nuclei  in  the 
brightly and  dimly  dansCsA-staining leukocytes was  com- 
pared (Fig. 4). Whereas 45% of the brightly dansCsA-stained 
cells had lobulated nuclei,  the FACS-II histographic distribu- 
tion of nuclear DNA content was 2N. A 2N distribution of 
nuclear  ethidium  bromide  fluorescence  was  found  in  the 
unlobulated nuclei of the dimly stained cells as well. Thus 
nuclear lobulation by CsA did not appear to reflect a capabil- 
ity special to nuclei entering mitosis. 
The  effects  of temperature,  metabolic  energy inhibitors, 
and calmodulin inhibitor R24571  on the extent of alteration 
of nuclear morphology by dansCsA were evaluated at 60 min 
Figure 5.  Nuclear  lobulation  at  60  rain:  comparison of temperature and drug effects. Mean  NMI  standard errors  for  100  nuclei in each 
condition were computed as described. The following concentrations were used: dansCsA and CsA at  1 ~M in PBS;  1 h  of pretreatment with 
dinitrophenol and 2-deoxyglucose at 0.5 mg/ml and 1 mg/ml, respectively; and calmodulin inhibitor R24571 at 1 #M. 
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Antibody  Cell type  Subject 1  Subject 2  Subject 3 
HLe I  Leukocyte  100  100  100 
Leu 1  Pan-T  70  70  85 
OKTII  Pan-T, SRBC  70  75  80 
OKT4  T  helper cell  70  70  75 
OKT8  Cytotoxic/supp.  <5  15  <5 
BI  Pan B  <5  <5  <5 
Leu 12  Pan B  <5  <5  <5 
IgM  Slg, B cell  <5  <5  <5 
OKM 1  Monocyte/gran.  30  40  30 
Tac  I 12 receptor  ND  <5  <5 
SRBC, sheep erythrocyte; supp., suppressor; gran., granulocyte; Slg,  surface 
immunoglobulin. 
* Peripheral blood lymphocytes were incubated with l ttM CsA for 1 h at 37"C 
before immunoperoxidase staining. 
were monocytes, as demonstrated by morphologic examina- 
tion and by staining with the OKM 1 monoclonal antibody. 
Discussion 
CsA and dansCsA rapidly induced lobulation of the nuclei of 
a  subpopulation  of human  peripheral  blood  mononuclear 
leukocytes in vitro in a dose-dependent manner. This striking 
alteration  in  nuclear  morphology induced  by CsA did  not 
affect cell viability, as assessed by trypan blue dye exclusion. 
The lobulation of the nuclei required both physiologic tem- 
perature and metabolic energy in Ca++-free PBS.  Leukocyte 
viability in the presence of 1.0 uM CsA is consistent with the 
known noncytotoxic immunosuppressive properties of CsA. 
The subpopulation of leukocytes susceptible to nuclear lobu- 
lation by CsA was identified by specific monoclonal antibody 
analyses as OKT4  ÷ T  cell lymphocytes, the T  helper subset 
responsible  for interleukin-2  production.  However,  not  all 
OKT4  ÷ lymphocytes demonstrated lobulated nuclei since the 
dim  staining  population  also  contained  this  T  cell  subset, 
which  did  not show lobulated nuclei.  Cellular drug uptake 
alone was not sufficient to induce nuclear lobulation, as 43% 
of the brightly fluorescent leukocytes treated with dansCsA 
maintained an ovoid nuclear morphology. 
CsA induces nuclear lobulation at a concentration sufficient 
to inhibit  calmodulin-specific phosphodiesterase activity in 
vitro (6), implicating a calmodulin-dependent process in nu- 
clear  lobulation.  Furthermore,  the  calmodulin  antagonists 
R24571  and  W-7,  while structurally different, have similar 
effects on  the  degree of nuclear lobulation,  as assessed by 
computer-assisted image analysis. Although the calmodulin 
inhibitors  W-7,  R24571,  and CsA all have nearly identical 
dissociation constants, CsA is twice as efficient as W-7 and 
R24571  in inducing nuclear lobulation after treatment. The 
efficiency of CsA in inducing nuclear lobulation, putatively 
through inhibition of calmodulin-dependent processes, may 
indicate that CsA is a  more efficient antagonist or that  its 
properties are unique  relative to those of other calmodulin 
antagonists. It will be important to study the relationship of 
CsA binding to calmodulin  and  identify what calmodulin- 
dependent functions are inhibited by this agent as compared 
with other calmodulin inhibitors. 
Calmodulin  antagonists  have  been  shown  previously to 
induce  structural  problems within  the  nucleus.  Treatment 
with the potent calmodulin antagonist trifluoroperazine can 
induce intranuclear paracystalline bundles of actin to form in 
HeLa  cells  (14).  Trifluoroperazine  also  causes  dramatic 
crenelations  in  HeLa cell  surface morphology, loss  of cell 
spreading, and  cell  locomotion, all of which are consistent 
with  derangement  of calmodulin-dependent  microfilament 
organization. In addition, calmodulin has been reported to be 
associated with  the cytoplasmic microtubular complex and 
the centrosomes (7).  Recent studies have indicated that the 
interactions of calmodulin  with these cytoskeletal elements 
regulate the Ca++-dependent depolymerization of these ele- 
ments (7). Lobulation of nuclei due to inhibition of calmod- 
ulin-dependent cytoskeletal elements has not been reported 
previously. The lobulated nuclei  induced by CsA or by the 
calmodulin  antagonists  appear to  splay chromatin  radially 
from a central hub which may reflect novel changes in the 
mechanical integrity of nuclear structural elements. The che- 
momechanical  mechanism  of  viable  nuclear  lobulation 
through calmodulin inhibition will require further experimen- 
tal dissection. However, the nuclear lobulations in T cells and 
monocytes may reflect mechanically interlocked cytoskeletal 
and nuclear skeletal elements that are calmodulin regulated. 
Myosin light chain kinase, Ca++-dependent calmodulin bind- 
ing protein, and calmodulin itself are mandatory cytoplasmic 
components for contractility in nonsmooth muscle and are 
identifiable components of the nuclear matrix (16). 
The effect of CsA on nuclear morphology in relation to its 
immunosuppressive activity remains unclear. However, this 
action  of CsA  may  cause  changes  in  the  cytoplasmic-to- 
nuclear signals necessary for T cell activation. CsA may prove 
to be a useful new noncytotoxic pharmacologic probe against 
calmodulin-dependent chemomechanical processes that influ- 
ence nuclear structure. 
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